Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:1
  • preuzimanja u poslednjih 30 dana:1
članak: 2 od 5  
Back povratak na rezultate
Vojnosanitetski pregled
2017, vol. 74, br. 2, str. 133-137
jezik rada: engleski
vrsta rada: izvorni naučni članak
doi:10.2298/VSP150619170M
Creative Commons License 4.0
Dijagnostički i patogenetski značaj apolipoproteinskih poremećaja kod bolesnika sa alkoholnom masnom jetrom
aUniverzitet u Nišu, Medicinski fakultet
bClinic of Gastroenterology and Hepatology, Clinical Center Niš, Niš

e-adresa: bovail@gmail.com

Sažetak

Uvod/Cilj. Alkohol je najčešći uzrok masne jetre. Metabolizam alkohola odvija se u jetri posredstvom alkoholne dehidrogenaze do toksičnog acetaldehida sa posledičnom akumulacijom masnih kiselina u jetri. Svakodnevnim unosom količina većih od 80 g/dan za muškarce, odnosno 20 g za žene, postoji rizik od razvoja alkoholne masne jetre. Cilj rada bio je da se utvrdi profil aterogenih faktora u plazmi bolesnika sa alkoholnom masnom jetrom (AFLD) u odnosu na bolesnike sa nealkoholnom masnom jetrom (NAFLD) i odredi njegov dijagnostički značaj. Metode. Studijom je bilo obuhvaćeno 74 bolesnika sa AFLD koji su konzumirali razno alkoholno piće u dnevnoj količini 80 g i više [za muškarce 3-4 jedinice (U) alkhola dnevno, a za žene 2-3 U]; kontrolnu grupu činilo je 70 bolesnika sa ultrazvučno potvrđenom NAFLD. Praćeni su ukupni holesterol (TC), trigliceridi (TG), lipoproteini velike gustine (HDL-C), lipoproteini male gustine (LDL-C) i apolipoproteini (ApoA1 i ApoB) i izračunavan je odnos TC/HDL-C, ApoB/ApoA1 i LDL-C/HDL-C. Rezultati. Studijom su bile obuhvaćene: grupe: I - 74 bolesnika (21% žena i 79% muškaraca) sa AFLD, prosečne starosti 42,65 ± 9,73 godina, koji su svakodnevno konzumirali alkoholne napitke u količini većoj od 80 g, tokom prosečno 2,31 ± 0,96 godina, i grupa II - 70 bolesnika sa NAFLD (37% žena i 63% muškaraca) prosečne starosti 41,3 ± 4,1 godina. Nije registrovana značajnija razlika u starosti i polu između ispitivanih grupa. Registrovane su značajno više vrednosti TG 9,94 ± 2,94 mmol/L, TC 14,53 ± 2,81 mmol/L, LDL-C 8,57 ± 2,15 mmol/L i Apo B 3,97 ± 0.28 g/L a niže vrednosti HDL-C 0,43 ± 0,11 mmol/L, Apo A1 0,49 ± 0,09 g/L i odnosa ApoB/ApoA1 2,43 ± 1,27, u grupi AFLD u odnosu na grupu NAFLD, (TG 8,74 ± 2,54 mmol/L, TC 9,87 ± 2,36 mmol/L, LDL-C 6,72 ± 1,98 mmol/L, Apo B 2,38 ± 0,16 g/L, HDL-C 0,78 ± 0,09 mmol/L, Apo A1 0,98 ± 0.04 g/L i ApoB/ApoA1 7,81 ± 1,42). Nije nađena značajna razlika u koncentraciji albumina, vrednostima international normalized ratio (INR), hemoglobina i hemotokrita između grupa. Zaključak. Vrednosti lipidnih frakcija i odnosa ApoB/ApoA1 uz markere hepatocelularnog oštećenja, mogu poslužiti kao dijagnostički kriterijum prisustva AFLD i biti dobar pokazatelj aterogenog rizika.

Ključne reči

Reference

*** (2006) Alcohol use and alcohol use disorders in the United States: Main findings from the 2001-2002 National Epidemiologic Survey on Alcohol Use and Related Conditions (NESARC). Bethesda, MD: National Epidemiologic Survey on Alcohol Use and Related Conditions (NESARC), http://www.ginasthma.org
*** (2005) Helping patients who drink too much: A clinician's guide. Bethesda, MD: National Institute of Health
Aalto, M., Seppä, K. (2005) Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. Alcohol and Alcoholism, 40(6): 520-523
Aertgeerts, B., Buntinx, F., Kester, A. (2004) The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis. Journal of Clinical Epidemiology, 57(1): 30-39
Alte, D., Luedemann, J., Rose, H., John, U. (2006) Laboratory Markers Carbohydrate-Deficient Transferrin, γ-Glutamyltransferase, and Mean Corpuscular Volume Are Not Useful as Screening Tools for High-Risk Drinking in the General Population: Results From the Study of Health in Pomerania (SHIP). Alcoholism: Clinical and Experimental Research, 28(6): 931-940
Anttila, P., Järvi, K., Latvala, J., Romppanen, J., Punnonen, K., Niemelä, O. (2005) Biomarkers of alcohol consumption in patients classified according to the degree of liver disease severity. Scandinavian Journal of Clinical and Laboratory Investigation, 65(2): 141-151
Barrio, E., Tom??, S., Rodr??guez, I., Gude, F., Sanchez-Leira, J., Perez-Becerra, E., Gonz??lez-Quintela, A. (2004) Liver Disease in Heavy Drinkers With and Without Alcohol Withdrawal Syndrome. Alcoholism: Clinical & Experimental Research, 28(1): 131-136
Chen, J. (2003) Combining carbohydrate-deficient transferrin and gamma-glutamyltransferase to increase diagnostic accuracy for problem drinking. Alcohol and Alcoholism, 38(6): 574-582
Daniel, J.R., Helen, H.H. (2012) Disorders of Lipoprotein metabolism. u: Longo D.L.; Fauci A.S.; Kasper D.L.; Hauser S.L.; Jameson J.L.; Lossalzo J. [ur.] Harrison's principles of internal medicine, New York: McGraw-Hill Medical Publisher Division, 3145-3161, 18th ed
Hannuksela, M.L., Liisanantti, M.K., Nissinen, A.E.T., Savolainen, M.J. (2007) Biochemical markers of alcoholism. Clinical Chemical Laboratory Medicine, 45(8): 953-61
Kamper-Jorgensen, M., Gronbaek, M., Tolstrup, J., Becker, U. (2004) Alcohol and cirrhosis: Dose-response or threshold effect. J Hepatol, 41(1); 25-30
Leevy, C.M., Moroianu, Ş.A. (2005) Nutritional Aspects of Alcoholic Liver Disease. Clinics in Liver Disease, 9(1): 67-81
Lefkowitch, J.H. (2005) Morphology of Alcoholic Liver Disease. Clinics in Liver Disease, 9(1): 37-53
Levitsky, J., Mailliard, M.E. (2004) Diagnosis and Therapy of Alcoholic Liver Disease. Seminars in Liver Disease, 24(3): 233-247
Lieber, C.S. (2004) New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Current Gastroenterology Reports, 6(1): 60-65
Mandayam, S., Jamal, M. M., Morgan, T.R. (2004) Epidemiology of Alcoholic Liver Disease. Seminars in Liver Disease, 24(3): 217-232
Mendez-Sanchez, N., Meda-Valdes, P., Uribe, M. (2005) Alcoholic liver disease. An update. Ann Hepatol, 4(1); 32-42
Niemela, O. (2007) Biomarkers in alcoholism. Clin Chim Acta, 377(1-2); 39-49
Nyblom, H. (2004) High ast/alt ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol and Alcoholism, 39(4): 336-339
Pedersen, T.R., Faergeman, O., Kastelein, J.J., Olsson, A.G., Tikkanen, M.J., Holme, I., i dr. (2004) Incremental Desrease and Events through Aggressive Lipid Lowering (IDEAL). Am J Cardiol, 94(6); 720-4
Pessione, F., Ramond, M-J., Peters, L., Pham, B-N., Batel, P., Rueff, B., Valla, D-C. (2003) Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver International, 23(1): 45-53
Rosengren, A., Hawken, S., Ounpuu, S., Sliwa, K., Zubaid, M., Almahmeed, W.A., Blackett, K.N., Sitthi-Chitr,, Sato, H., Yusuf, S., INTERHEART investigators (2004) Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): Case-control study. Lancet, 364(9438): 953-62
Shiffman, R.N., Shekelle, P., Overhage, J.M., Slutsky, J., Grimshaw, J., Deshpande, A.M. (2003) Standardized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guideline Standardization. Annals of Internal Medicine, 139(6): 493
Sougioultzis, S., Dalakas, E., Hayes, P. C., Plevris, J. N. (2005) Alcoholic hepatitis: from pathogenesis to treatment. Current Medical Research and Opinion, 21(9): 1337-1346
Trabut, J.-B., Plat, A., Thepot, V., Fontaine, H., Vallet-Pichard, A., Nalpas, B., Pol, S. (2008) Influence of Liver Biopsy on Abstinence in Alcohol-Dependent Patients. Alcohol and Alcoholism, 43(5): 559-563
Yoon, Y.H., Yi, H.Y. (2006) Surveillance report #75: Liver cirrhosis mortality in the United States, 1970-2003. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism